en · de · es · fr · pt
aod-9604-notes.peptides3081.com › Faq › Research And Regulatory Status — Research Overview

Research And Regulatory Status — Research Overview

By Editorial Desk · published 2025-10-20 · last reviewed 2025-11-14 · Faq

This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2025-11-14. Anything still debated is marked as such rather than presented as settled.

Research and Regulatory Status

AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.

Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.

Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.

Handling And Analytical Properties

AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.

Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.

Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.

Aod-9604 at a glance

PropertyValueNotes
Primary research areaObesity and metabolic regulationStudied in cell, animal, and human models
Highest reported trial phasePhase IIPublic summaries describe mixed results
Common route in trialsSubcutaneous injectionTypical for peptide therapeutics
Regulatory example2013 Australian anti-doping reviewClassification was debated at the time
Approval statusNot approved as a human medicineStatus can change by jurisdiction

Mechanism and Regulatory Status

Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.

Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.

Related pages on this site

Regulation and Detection Context

AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.

Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.

Notes from published material

=== Possible uses === While gliotoxin exposure at high concentrations shows cytotoxic effects via a multitude of different pathways, low-dose gliotoxin has been shown to have beneficial biological functions. Low-dose gliotoxin can exert antioxidant activities in the presence of the thioredoxin redox system that can counter the release of ROS in cells as a result of the electron transport chain (ETC) during cellular respiration. Moderate doses of gliotoxin have also been found to exhibit an anti-inflammatory effect in vivo due to the suppression of NF-κB activity by gliotoxin. Doses of gliotoxin less than 40 nM can also activate latent HIV-1 gene expression, serving as a diagnostic of HIV infection. Gliotoxin can activate HIV-1 expression by targeting (LARP7), which results in the release of active P-TEFb and the positive regulation of transcription of HIV proteins. Treatment of 20 nM gliotoxin reversed HIV-1 latency without interfering in the activation of CD4+ or CD8+ T-cells that are involved in the elimination of HIV-infected cells. While research on this possible gliotoxin use is in early stages, this provides a possible future direction for HIV diagnosis and treatment.

The president of the Republic of the Union of Myanmar (Burmese: နိုင်ငံတော်‌သမ္မတ, MLCTS: nuing ngam tau samma.ta., lit. 'President of the State') is the head of state and head of government of Myanmar. The president chairs the National Defence and Security Council and leads the Union Government (Cabinet), the executive branch of the Myanmar government. The presidency was established in 1948, when Burma gained its independence from the British Empire. During this period, the president was the ceremonial head of state while prime minister is the actual head of government. The presidency was abolished following the 1962 coup d'etat, when Ne Win assumed the powers of both head of state and head of government as the Chairman of the Revolutionary Council and the Revolutionary Government. The 1974 Constitution reintroduced the presidency, to be held by the Chairman of the Council of State. The 1988 coup d'etat again led to the presidency's abolishment, with the Chairman of the State Law and Order Restoration Council (reconstituted in 1997 as the State Peace and Development Council) assuming the functions of the head of state. The 2008 Constitution introduced a presidential system, where the president is both the head of state and government. Thein Sein assumed the presidency in 2011. After the 2015 election, the extraconstitutional post of State Counsellor of Myanmar was created for Aung San Suu Kyi, the leader of the majority party, the National League for Democracy, because she was ineligible for the presidency.

A high capacity for long-term storage of retinol means that well-nourished humans can go months on a vitamin A-deficient diet, while maintaining blood levels in the normal range. Only when the liver stores are nearly depleted will signs and symptoms of deficiency show. Retinol is reversibly converted to retinal, then irreversibly to retinoic acid, which activates hundreds of genes. Vitamin A deficiency is common in developing countries, especially in Sub-Saharan Africa and Southeast Asia. Deficiency can occur at any age but is most common in pre-school age children and pregnant women, the latter due to a need to transfer retinol to the fetus. Vitamin A deficiency is estimated to affect approximately one-third of children under the age of five around the world, resulting in hundreds of thousands of cases of blindness and deaths from childhood diseases because of immune system failure. Reversible night blindness is an early indicator of low vitamin A status. Plasma retinol is used as a biomarker to confirm vitamin A deficiency. Breast milk retinol can indicate a deficiency in nursing mothers. Neither of these measures indicates the status of liver reserves. The European Union and various countries have set recommendations for dietary intake, and upper limits for safe intake. Vitamin A toxicity also referred to as hypervitaminosis A, occurs when there is too much vitamin A accumulating in the body. Symptoms may include nervous system effects, liver abnormalities, fatigue, muscle weakness, bone and skin changes, and others.

Sources: en.wikipedia.org

Further detail

== Toxicity == While members of the Liliaceae s.s. have been used as food sources in humans, the bulbs of some species are poisonous to household pets (bulb toxicosis) if eaten and may cause serious complications, such as kidney failure in cats from Lilies, particularly Lilium longiflorum (Easter Lily). Dogs may develop less serious effects such as gastrointestinal problems and central nervous system depression. Most Fritillaria (e.g. F. imperialis, F. meleagris) bulbs contain poisonous neurotoxic alkaloids such as imperialin (peiminine), which may be deadly if ingested in quantity, while other species such as Fritillaria camschatcensis and Fritillaria affinis are edible. Tulips can cause skin irritation due to the presence of tuliposides and tulipalins, which are also found in the flowers, leaves and stems of Fritillaria. These are also toxic to a variety of animals.

extein Any part of an amino acid sequence which is retained within a precursor polypeptide, i.e. not excised by post-translational protein splicing, and is therefore present in the mature protein, analogous to the exons of RNA transcripts. Contrast intein.

Another big step forward was using machine learning methods. First artificial neural networks methods were used. As a training sets they use solved structures to identify common sequence motifs associated with particular arrangements of secondary structures. These methods are over 70% accurate in their predictions, although beta strands are still often underpredicted due to the lack of three-dimensional structural information that would allow assessment of hydrogen bonding patterns that can promote formation of the extended conformation required for the presence of a complete beta sheet. PSIPRED and JPRED are some of the most known programs based on neural networks for protein secondary structure prediction. Next, support vector machines have proven particularly useful for predicting the locations of turns, which are difficult to identify with statistical methods. Extensions of machine learning techniques attempt to predict more fine-grained local properties of proteins, such as backbone dihedral angles in unassigned regions. Both SVMs and neural networks have been applied to this problem. More recently, real-value torsion angles can be accurately predicted by SPINE-X and successfully employed for ab initio structure prediction.

Sources: en.wikipedia.org

Frequently asked questions

Has AOD-9604 been approved as a medicine?

No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.

Why is AOD-9604 discussed in anti-doping?

It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.

What did human trials of AOD-9604 find?

Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.

How should AOD-9604 be stored?

Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.

Network